Abstract:Purinergic signaling is a crucial determinant in the regulation of pulmonary vascular physiology and presents a promising avenue for addressing lung diseases. This intricate signaling system encompasses two primary receptor classes: P1 and P2 receptors. P1 receptors selectively bind adenosine, while P2 receptors exhibit an affinity for ATP, ADP, UTP, and UDP. Functionally, P1 receptors are associated with vasodilation, while P2 receptors mediate vasoconstriction, particularly in basally relaxed vessels, through modulation of intracellular Ca 2+ levels. The P2X subtype receptors facilitate extracellular Ca 2+ influx, while the P2Y subtype receptors are linked to endoplasmic reticulum Ca 2+ release. Notably, the primary receptor responsible for ATP-induced vasoconstriction is P2X1, with α,β-meATP and UDP being identified as potent vasoconstrictor agonists. Interestingly, ATP has been shown to induce endothelium-dependent vasodilation in pre-constricted vessels, associated with nitric oxide (NO) release. In the context of P1 receptors, adenosine stimulation of pulmonary vessels has been unequivocally demonstrated to induce vasodilation, with a clear dependency on the A 2B receptor, as evidenced in studies involving guinea pigs and rats. Importantly, evidence strongly suggests that this vasodilation occurs independently of endothelium-mediated mechanisms. Furthermore, studies have revealed variations in the expression of purinergic receptors across different vessel sizes, with reports indicating notably higher expression of P2Y 1 , P2Y 2 , and P2Y 4 receptors in small pulmonary arteries. While the existing evidence in this area is still emerging, it underscores the urgent need for a comprehensive examination of the specific characteristics of purinergic signaling in the regulation of pulmonary vascular tone, particularly focusing on the disparities observed across different intrapulmonary vessel sizes. Consequently, this review aims to meticulously explore the current evidence regarding the role of purinergic signaling in pulmonary vascular tone regulation, with a specific emphasis on the variations observed in intrapulmonary vessel sizes. This endeavor is critical, as purinergic signaling holds substantial promise in the modulation of vascular tone and in the proactive prevention and treatment of pulmonary vascular diseases.

Purinergic signalling in the liver in health and disease

Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities

Purinergic Signaling in Non-Parenchymal Liver Cells

Purinergic signaling in liver disease: calcium signaling and induction of inflammation

From purines to purinergic signalling: molecular functions and human diseases

Introduction to Purinergic Signaling

Purinergic signalling in endocrine organs

Cardiac purinergic signalling in health and disease

Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death

Purinergic signalling and immune cells

Purine and purinergic receptors in health and disease

Purine and purinergic receptors

Synapomorphic features of hepatic and pulmonary vasculatures include comparable purinergic signaling responses in host defense and modulation of inflammation

Purinergic signaling: Diverse effects and therapeutic potential in cancer

Purinergic Signaling in Pulmonary Inflammation

The role of the CD39–CD73–adenosine pathway in liver disease

Blood cells: an historical account of the roles of purinergic signalling

Editorial - Purinergic signalling: 50 years

Purinergic regulation of pulmonary vascular tone

Comprehensive Insights into Potential Roles of Purinergic P2 Receptors on Diseases: Signaling Pathways Involved and Potential Therapeutics

Purinergic regulation of the immune system